首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1917897

DNA合成儀市場－2026-2031年預測

DNA Synthesizer Market - Forecast from 2026 to 2031

出版日期: 2026年01月08日 | 出版商:

Knowledge Sourcing Intelligence | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

DNA合成儀市場預計將從2025年的4.4063億美元成長到2031年的10.24688億美元，複合年成長率為15.1%。

DNA合成儀市場是生命科學工具產業中重要且快速發展的細分市場，為寡核苷酸和合成基因的人工合成和從頭合成提供關鍵的設備和平台。這些自動化系統使研究人員能夠根據數位輸入建立客製化的DNA序列，從而為包括合成生物學、治療方法開發和分子診斷在內的廣泛應用奠定基礎。該市場的特點是技術從傳統的亞磷醯胺化學轉變為新型酶法轉變，桌上型自動化技術的進步，以及與高通量工業工作流程的日益整合。推動市場成長的因素包括：合成生物學的廣泛應用和不斷成長的需求、藥物研發流程的加速推進，以及對更快、更便捷、更精確的DNA建構方法的需求。

推動合成生物學發展的主要動力之一是對合成生物學研究及其商業應用的大量且不斷成長的投資。合成生物學致力於設計和建構新的生物構件和系統，根本在於能夠像讀取DNA一樣輕鬆地編寫DNA。其應用範圍廣泛，涵蓋了從用於工業生物技術和農業的工程微生物到新型疫苗、細胞和基因療法以及基於DNA的數據存儲的開發。該領域的擴張正在創造對合成DNA的持續且巨大的需求，從而推動了對更高通量、更長構建時間和更低錯誤率的合成設備的需求，以支持日益雄心勃勃的計劃。

與此密切相關的是DNA合成在現代藥物發現和治療方法開發中的關鍵作用。製藥和生物技術產業高度依賴客製化DNA進行標靶檢驗、抗體開發、CRISPR引導RNA合成以及基因治療病毒載體建構。 mRNA療法和疫苗的興起進一步加劇了這種需求，因為這些治療方法需要精確合成長鏈、序列最佳化的RNA模板。 DNA合成儀是加速研發進程的關鍵工具，因此需要能夠無縫整合到自動化、高通量工作流程中的平台，以提高藥物開發平臺的效率並縮短週期。

桌上型DNA合成儀的需求不斷成長，技術也日趨創新，這是市場的關鍵趨勢。傳統上，DNA合成要么在大型集中式核心實驗室進行，要么外包給服務供應商。而緊湊易用的桌上型儀器的出現，使得合成過程分散化，將寡核苷酸的生產直接引入學術界、生物技術和製藥實驗室。這些系統為研究人員提供了即時、按需獲取客製化寡核苷酸的途徑，顯著加快了實驗迭代速度，並保護了智慧財產權。這種實驗室規模自動化的趨勢，使合成能力惠及更廣泛的終端使用者群體，從而擴大了潛在市場。

技術創新，尤其是酶促DNA合成（EDS）的出現，代表市場潛在的模式轉移。固相亞磷醯胺化學方法幾十年來一直是行業標準，但酶方法展現出許多優勢，包括減少有害溶劑的使用、實現更長時間、更精確的合成，以及為更環保的生產方式鋪平道路。開發EDS平台的公司正著眼於實驗室規模和可擴展的工業應用，將這項技術定位為顛覆性創新，並有望在未來幾年內重新定義合成的經濟性和能力。

此外，合成DNA在分子診斷和個人化醫療領域的應用日益廣泛，推動了市場的發展。客製化寡核苷酸是PCR檢測、次世代定序平台和各種診斷探針的關鍵組成部分。隨著精準醫療的進步和分子診斷項目的擴展，可靠且經濟高效地合成這些特定DNA序列的需求日益成長，從而滿足了診斷領域持續成長的需求。

從區域來看，北美保持著市場主導地位。這一主導地位得益於該地區聚集了眾多大型生物技術和製藥公司、頂尖學術研究機構，為合成生物學Start-Ups提供了充足的創業投資投資，以及成熟的生命科學創新生態系統。眾多大型合成設備製造商的存在，加上該地區積極採用新技術的文化，進一步鞏固了北美作為先進DNA合成平台領先市場的地位。

競爭格局包括提供亞磷醯胺基設備的成熟公司、開創酶促合成新興企業的創新新創企業，以及開發專有合成技術的大型服務供應商。競爭的焦點在於關鍵性能指標：合成速度、通量、長序列定序能力（讀取長度和通量）、序列準確性（錯誤率）、鹼基成本以及與實驗室自動化系統的整合便捷性。策略活動通常涉及與製藥和合成生物學公司合作，共同開發客製化解決方案。

總之，DNA合成儀市場正從寡核苷酸生產的利基工具轉型為支持蓬勃發展的生物經濟的核心技術。其成長軌跡與合成生物學的擴張以及生物數位化在治療方法和診斷領域的進步密不可分。未來市場發展將受到酵素合成技術的成功商業化和規模化、桌上型系統的持續小型化和自動化，以及產業降低成本和提高長DNA構建體保真度的能力等因素的影響。市場參與企業的成功取決於其能否提供可靠、擴充性且以用戶為中心的平台，使研究人員能夠以前所未有的速度和精度將基因設計轉化為物理現實。

本報告的主要優勢：

深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及影響、新產品開發、競爭影響

分析範圍

歷史資料（2021-2025 年）和預測資料（2026-2031 年）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按業務板塊和地區（國家）分類的收入成長和預測分析
公司概況（策略、產品、財務資訊、關鍵趨勢等）

The DNA synthesizer market is a critical and rapidly evolving segment within the life sciences tools industry, providing the instrumentation and platforms essential for the artificial, de novo creation of oligonucleotides and synthetic genes. These automated systems enable researchers to construct custom DNA sequences from digital inputs, forming the foundational material for a vast range of applications in synthetic biology, therapeutic development, and molecular diagnostics. The market is characterized by a technological shift from traditional phosphoramidite chemistry toward novel enzymatic methods, a move toward benchtop automation, and increasing integration into high-throughput industrial workflows. Growth is driven by the expansive and growing needs of synthetic biology, accelerating drug discovery pipelines, and the demand for faster, more accessible, and higher-fidelity DNA construction.

A primary and powerful driver is the substantial and rising investment in synthetic biology research and its commercial applications. Synthetic biology, which involves the design and construction of new biological parts and systems, is fundamentally dependent on the ability to write DNA as readily as it can be read. Applications span from engineered microbes for industrial biotechnology and agriculture to the development of novel vaccines, cell and gene therapies, and DNA-based data storage. The expansion of this field creates sustained, high-volume demand for synthetic DNA, pushing the need for synthesizers that offer greater throughput, longer construct lengths, and lower error rates to support increasingly ambitious projects.

Closely aligned is the critical role of DNA synthesis in modern drug discovery and therapeutic development. The pharmaceutical and biotechnology industries rely heavily on custom DNA for target validation, antibody development, CRISPR guide RNA synthesis, and the construction of viral vectors for gene therapy. The rise of mRNA therapeutics and vaccines has further amplified this demand, as these modalities require the precise synthesis of long, sequence-optimized RNA templates. DNA synthesizers are integral tools for accelerating these R&D timelines, creating demand for platforms that integrate seamlessly into automated, high-throughput workflows to improve productivity and reduce cycle times in drug development pipelines.

A significant market trend is the growing demand for and innovation in benchtop DNA synthesizers. Traditionally, DNA synthesis was performed by large, centralized core facilities or outsourced to service providers. The advent of compact, user-friendly benchtop instruments is decentralizing synthesis, bringing oligo production directly into individual academic, biotech, and pharmaceutical labs. These systems offer researchers immediate, on-demand access to custom oligonucleotides, significantly speeding experimental iteration and protecting intellectual property. This trend toward lab-scale automation is expanding the total addressable market by placing synthesis capability in the hands of a broader base of end-users.

Technological innovation, particularly the emergence of enzymatic DNA synthesis (EDS), represents a potential paradigm shift within the market. While solid-phase phosphoramidite chemistry has been the industry standard for decades, enzymatic methods offer promising advantages, including reduced use of hazardous solvents, the potential for longer and more accurate synthesis, and a pathway to greener manufacturing. Companies developing EDS platforms are targeting both benchtop and scalable industrial applications, positioning this technology as a key disruptive force that could redefine synthesis economics and capabilities in the coming years.

The market is further fueled by the expanding application of synthetic DNA in molecular diagnostics and personalized medicine. Custom oligonucleotides are essential components for PCR assays, next-generation sequencing panels, and various diagnostic probes. As precision medicine advances and the menu of molecular diagnostics grows, so does the need for reliable, cost-effective synthesis of these specific DNA sequences, supporting steady demand from the diagnostics sector.

Geographically, North America maintains a dominant market position. This leadership is anchored in the region's concentration of leading biotechnology and pharmaceutical companies, top-tier academic research institutions, substantial venture capital funding for synthetic biology startups, and a mature ecosystem for life sciences innovation. The presence of many key synthesizer manufacturers and a culture of early technology adoption further reinforce North America's role as the primary market for advanced DNA synthesis platforms.

The competitive landscape includes established providers of phosphoramidite-based instrumentation, innovative startups pioneering enzymatic synthesis, and large-scale service providers that also develop proprietary synthesis technologies. Competition centers on key performance metrics: synthesis speed, throughput, length capability (read length and throughput), sequence accuracy (error rate), cost per base, and ease of integration into laboratory automation. Strategic activities often involve partnerships with pharmaceutical companies or synthetic biology firms to co-develop tailored solutions.

In conclusion, the DNA synthesizer market is transitioning from a niche tool for oligo production to a central enabling technology for the burgeoning bioeconomy. Its growth trajectory is inextricably linked to the expansion of synthetic biology and the increasing biological digitization of therapeutics and diagnostics. Future market development will be shaped by the successful commercialization and scaling of enzymatic synthesis, continued miniaturization and automation of benchtop systems, and the industry's ability to drive down the cost and increase the fidelity of long DNA constructs. Success for market participants will depend on delivering reliable, scalable, and user-centric platforms that empower researchers to translate genetic designs into physical reality with unprecedented speed and precision.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

DNA Synthesizer Market Segmentation

By Type
Benchtop DNA Synthesizer
Large-Scale DNA Synthesizer
By Application
Drug Discovery
Genetic Engineering
Clinical Diagnostics
Others
By End-User
Pharmaceutical & Biotech Companies
Academic & Research Institutes
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. DNA SYNTHESIZER MARKET BY TYPE

5.1. Introduction
5.2. Benchtop DNA Synthesizer
5.3. Large-Scale DNA Synthesizer

6. DNA SYNTHESIZER MARKET BY APPLICATION

6.1. Introduction
6.2. Drug Discovery
6.3. Genetic Engineering
6.4. Clinical Diagnostics
6.5. Others

7. DNA SYNTHESIZER MARKET BY END-USER

7.1. Introduction
7.2. Pharmaceutical & Biotech Companies
7.3. Academic & Research Institutes
7.4. Others

8. DNA SYNTHESIZER MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others